Predicting Memory Decline as a Risk Factor for Alzheimer\u27s Disease in Older Post-Menopausal Women: Quod Erat Demonstrandum? by Rodrigues, Mark et al.
Edith Cowan University 
Research Online 
ECU Publications Pre. 2011 
1-1-2010 
Predicting Memory Decline as a Risk Factor for Alzheimer's 
Disease in Older Post-Menopausal Women: Quod Erat 
Demonstrandum? 
Mark Rodrigues 
Edith Cowan University 
Jonathan Foster 
Edith Cowan University 
Giuseppe Verdile 
Edith Cowan University 
Karen Joesbury 
Richard Prince 
See next page for additional authors 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworks 
 Part of the Medicine and Health Sciences Commons 
10.1017/S1041610209991190 
This is an Author's Accepted Manuscript of: Rodrigues, M. A., Foster, J. K., Verdile, G. , Joesbury, K., Prince, R., 
Devine, A. , Mehta, P., Beilby, J., & Martins, R. N. (2010). Predicting memory decline as a risk factor for Alzheimer's 
disease in older post-menopausal women: Quod erat demonstrandum?. International Psychogeriatrics, 22(2), 
332-335. Available here 
This version is free to view and download for private research and study only. Not for re-distribution, re-sale or use 
in derivative works. © International Psychogeriatrics. 
This Journal Article is posted at Research Online. 
https://ro.ecu.edu.au/ecuworks/6367 
Authors 
Mark Rodrigues, Jonathan Foster, Giuseppe Verdile, Karen Joesbury, Richard Prince, Amanda Devine, 
Pankaj Mehta, John Beilby, and Ralph Martins 
This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworks/6367 
International Psychogeriatrics (2010), 22:2, 332–339 C© International Psychogeriatric Association 2009
L E T T E R S
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Predicting memory decline as a risk factor for
Alzheimer’s disease in older post-menopausal
women: quod erat demonstrandum?
Alzheimer’s disease (AD) is the major form of age-
related dementia worldwide, accounting for more
than two-thirds of all dementia cases. The disease is
characterized by a progressive loss of cognitive and
intellectual functioning (Gilman, 1997). A number
of risk factors for AD have been identified. The
prevalence of AD increases with age, diabetes,
depression, family history of Parkinson’s disease
and following head injury or exposure to solvents
(Jorm et al., 1991; van Duijn et al., 1991; Ott
et al., 1995; Yoshitake et al., 1995; Devanand
et al., 1996). Published research further suggests
that low education levels are associated with
increased prevalence of clinical AD (Gatz et al.,
2001; Qiu et al., 2001; Ravaglia et al., 2002).
Women also have a higher risk for developing the
disease than men, with the risk being markedly
increased following menopause (Sherwin, 2002;
Sherwin 2003). Additionally, slightly more severe
cognitive deficits have been reported in AD in
women compared to men (Buckwalter et al.,
1993, Henderson and Buckwalter, 1994). These
epidemiological trends may be a consequence of
reproductive hormonal changes. Specifically, men-
opause results in a marked diminution in gonadal
estrogen production in women (see Sherwin, 2003,
for a review). Estrogen plays a pivotal role in the
maintenance and function of neuronal circuits in
the brain and in resistance to neuronal damage
(McEwen, 2001). The neuroprotective properties
of estrogen are thought to be mediated at least
in part by anti-amyloidogenic, anti-oxidative and
ant-inflammatory mechanisms (reviewed in Barron
et al., 2006a). However, limited and somewhat
mixed data exist regarding the association between
endogenous levels of estrogen and cognitive decline
(Manly et al., 2000; Schupf et al., 2003). Based on
some of our own findings, we here consider the
factors that may be useful in predicting memory
decline as a risk factor for Alzheimer’s disease in
older post-menopausal women.
We have previously noted the relationship
between reproductive hormones (estrogen, leu-
tinizing hormone (LH) and follicle stimulating
hormone (FSH)) and global cognitive status in a
large cohort of over 500 postmenopausal women
(Rodrigues et al., 2008). However, with respect
to the symptomatology of early stage AD, specific
deficits in episodic learning and memory are the
most commonly occurring cognitive signs of the
disease (Collie and Maruff, 2000; Remy et al.,
2005). We have noted a lack of independent
or combined association between endogenous
estrogen status and episodic memory capacity in
the same cohort of over 500 older postmenopausal
women studied by Rodrigues et al. (2008). This
finding was observed despite the fact that the
relatively large dataset allowed for the application
of powerful statistical techniques, specifically with
respect to multiple linear regression. This outcome
is consistent with our previous report (Rodrigues
et al., 2008) that estrogen did not have a statistically
significant impact on global cognitive status in
the same cohort; instead, gonadotropins, LH
and FSH showed significant associations with
global cognition. Further, gonadotropins have been
reported to exert a significant role in AD risk and
pathogenesis (reviewed in Barron et al., 2006b).
However, in contrast to our findings, other studies
have reported that endogenous estrogen does exert
a significant effect on cognition (Drake et al., 2000;
Senanarong et al., 2002; Wolf and Kirschbaum,
2002; Yaffe et al., 2000), and that estrogen shows no
associations with gonadotropin levels (Hoskin et al.,
2004; Tsolaki et al., 2005). The discrepancies that
exist in these studies merit further consideration,
specifically with respect to issues concerning sample
size, age of cohort, presence of other AD-associated
risk factors (including the APOE ε4 allele) and the
type of cognitive capacity being evaluated.
A specific threshold for estrogen may exist
in relation to its influence on cognition: it
is possible that clinically measurable effects of
estrogen on cognition may only occur at higher
concentrations (for example, after exogenous
estrogen administration), compared with levels
that are naturally present in post-menopausal
women. In this context, it is relevant that several
studies using measures of episodic memory have
found an improvement in cognitive performance
after exogenous estrogen replacement therapy
(Phillips and Sherwin, 1992; Kampen and Sherwin,
1994; Jacobs et al., 1998; Burkhardt et al.,
2004). Indeed, considering the substantial number
of investigations into the effects of estrogen
administration on memory in post-menopausal
women, it is perhaps surprising that relatively little
evidence exists concerning the relationship between
endogenous estrogen concentration and episodic
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memory. Exogenous treatments of estrogen in post-
menopausal women may better match the naturally
occurring biological levels found in pre-menopausal
women, and may be more likely to have a significant
impact on memory and learning. Further, given that
the findings the we note here were obtained in a
relatively older cohort (aged 75–86 years; Rodrigues
et al., 2008), it is possible that women’s endogenous
estrogen levels in the earlier post-menopause years
are more strongly associated with episodic memory
functioning.
We further observed in this cohort (Rodrigues
et al., 2008) that the possession of an APOE ε4 allele
did not have a statistically significant impact on
verbal episodic memory performance. This finding
is again consistent with our previous investigation
of global cognitive status in this cohort of older
post-menopausal women (Rodrigues et al., 2008).
This point notwithstanding, considerable empirical
evidence exists regarding the APOE genotype and
its role in modifying the risk of age-related cognitive
decline and AD. However, the presence of the
ε4 allele is associated with less than 50% of the
population of patients with AD (Evans et al., 1997).
Furthermore, this allele may not be a significant
risk factor in all ethnic groups (Evans et al., 2003).
In this cohort of post-menopausal women, other
modulating factors such as education, age and other
relevant biomarkers may have attenuated the impact
of APOE genotype. We believe that this issue also
warrants further discussion and investigation.
Elderly people have an enhanced risk of depress-
ive disorders and symptoms (Wells et al., 1989; Judd
and Akiskal, 2000; Judd et al., 2000). Moreover,
a number of studies have reported a potentially
important link between age-related depression
and memory decline (Kral, 1983; Alexopoulos
et al., 1993; Devanand et al., 1996). In our cohort
(Rodrigues et al., 2008), depression was found not
to be a significant factor associated with episodic
learning or memory performance. The existing
literature suggests that symptoms of depression can
have quite specific effects on elements of cognitive
functioning. This consideration might be highly
relevant in this context.
Our data were consistent with established
findings linking increased age, reduced educational
level and increased blood-borne beta amyloid to
lower episodic memory capacity. Further, one
element of memory capacity that was evaluated
(delayed recognition performance) was significantly
associated with statin use and with hypertension
status in this cohort (Rodrigues et al., 2008).
Statins are used as pharmaceutical agents to reduce
plasma levels of cholesterol, by inhibiting the
activity of the enzyme 3-hydroxy-3-methyl-glutaryl-
coenzyme. Accumulating evidence suggests that the
use of statins lowers the risk of dementia, most
likely via amyloid-related mechanisms (Jick et al.,
2000; Fassbender et al., 2001; Pedrini et al., 2005).
Statins may also improve endothelial homeostasis by
increasing the accessibility of nitric oxide (Vaughan,
2003), which may facilitate chemical messaging
between cells.
Our findings indicated that hypertension was
a risk factor for lower episodic memory capacity.
A number of previous studies have linked high
arterial blood pressure to increased risk of late-life
dementia and cognitive decline (Knopman et al.,
2001; van Dijk et al., 2004; Whitmer et al.,
2005). Indeed, studies have reported that
hypertension may increase the rate of cognitive
decline both in patients with AD (Hanon et al.,
2003) and in controls (Bellew et al., 2004).
However, other studies have indicated no significant
association between hypertension and age-related
decline in cognitive performance (Farmer et al.,
1987, 1990; Scherr et al., 1991; van Boxtel et al.,
1998). With respect to our own findings pertaining
to hypertension, high blood pressure may cause
cerebrovascular disease (particularly ischemia),
including relatively minor but chronic disturbances
in cerebral perfusion, producing unfavorable effects
on brain cell metabolism (Elias et al., 1993).
These changes may increase the likelihood that
individuals with incipient AD pathology will express
symptoms of dementia, including cognitive decline.
Hypertension may also accelerate the AD process
directly (Skoog and Gustafson, 2003), insofar as
similar biological mechanisms may be involved in
the pathogenesis of both hypertension and AD.
In summary, we have noted here that, in our
cohort (Rodrigues et al., 2008) age, beta amyloid
concentration and hypertension were negatively
associated with episodic memory function, whereas
education and statin use had positive associations
with episodic memory. A relationship between
endogenous estrogen and memory functioning was
not evident. In future, additional insight will be
gained from extended longitudinal investigations
of similar cohorts, employing a wider range of
cognitive and functional assessments in enriched
groups of individuals who are at increased risk
of prodromal AD. Further, although a wealth
of literature exists on the relationship between
reproductive hormones and cognitive decline, AD
risk and AD pathogenesis, the precise role of
estrogen still remains unclear. This is reiterated in
the controversy that exists concerning the putative
benefits of hormone replacement therapy for
improving cognitive capacity and as a therapeutic
for AD (for recent review and meta analysis, see
334 Letters
Hogervorst et al., 2009). It is clear that in future
large clinical studies which control for a number of
relevant factors (as adumbrated herein) are required
to address some of the discrepancies in the extant
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